Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pexastimogene devacirepvec
- Development stage
- Phase 3
- Lead developer
- SillaJen
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
Pexastimogene devacirepvec (Pexa-Vec) is an oncolytic immunotherapy based on a modified Wyeth strain of the vaccinia virus. It is engineered for tumor selectivity through the deletion of the viral thymidine kinase (TK) gene, which restricts viral replication to proliferating cancer cells with high cellular TK levels. Additionally, the virus is engineered to express the human granulocyte-macrophage colony-stimulating factor (GM-CSF) transgene to stimulate a systemic anti-tumor immune response. Pexa-Vec exerts its therapeutic effect through three primary mechanisms: direct oncolysis (viral replication leading to cell bursting), induction of active anti-tumor immunity, and disruption of tumor vasculature. While it was primarily developed for hepatocellular carcinoma (HCC), its development in that indication was significantly impacted by the termination of the Phase 3 PHOCUS trial. It continues to be investigated in various solid tumors, often in combination with immune checkpoint inhibitors like ipilimumab or cemiplimab.
- Brand names
- Pexa-Vec
- Other names
- pexastimogene devacirepvec
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TK2 (Thymidine kinase 2)
Beyond the preview
Go deeper on pexastimogene devacirepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pexastimogene devacirepvec.